TNF blockers on every 2026 Delaware Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 10 stand-alone Part D plans in Delaware cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
| Drug | Humana Basic Rx Plan$0.00/moS5884-103 | Humana Value Rx Plan$4.30/moS5884-184 | Wellcare Value Script$5.60/moS4802-140 | Wellcare Classic$5.70/moS4802-079 | HealthSpring Assurance Rx$32.60/moS5617-214 | AARP Medicare Rx Saver from UHC$37.80/moS5921-350 | HealthSpring Extra Rx$66.60/moS5617-355 | AARP Medicare Rx Preferred from UHC$94.50/moS5921-387 | SilverScript Choice$97.40/moS5601-010 | Humana Premier Rx Plan$108.60/moS5884-151 |
|---|---|---|---|---|---|---|---|---|---|---|
| Humiraadalimumab | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Tier 5PA25%QL 52/365d | Not covered |
| adalimumab biosimilarsadalimumab-adaz, -fkjp, -aacf and others | Tier 5PA25%QL 0.2/28d | Tier 5PA26%QL 0.2/28d | Tier 5PA25%QL 4/28d | Tier 5PA25%QL 4/28d | Not covered | Tier 5PA25% | Not covered | Tier 5PA31% | Not covered | Tier 5PA33%QL 0.2/28d |
| Hadlimaadalimumab-bwwd | Not covered | Not covered | Not covered | Not covered | Tier 5PA25%QL 2.4/28d | Not covered | Tier 5PA25%QL 2.4/28d | Not covered | Tier 5PA25%QL 22.4/365d | Not covered |
| Hyrimozadalimumab-adaz | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Cyltezoadalimumab-adbm | Not covered | Not covered | Tier 5PA25%QL 4/28d | Tier 5PA25%QL 4/28d | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Simlandiadalimumab-ryvk | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Yuflymaadalimumab-aaty | Not covered | Not covered | Tier 5PA25%QL 2/28d | Tier 5PA25%QL 2/28d | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Amjevitaadalimumab-atto | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Enbreletanercept | Tier 5PA25%QL 8/28d | Tier 5PA26%QL 8/28d | Tier 5PA25%QL 8/28d | Tier 5PA25%QL 8/28d | Tier 5PA25%QL 8/28d | Tier 5PA25%QL 4/28d | Tier 5PA25%QL 8/28d | Tier 5PA31%QL 4/28d | Tier 5PA25%QL 8/28d | Tier 5PA33%QL 8/28d |
| Cimziacertolizumab pegol | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Simponigolimumab | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.